Influence of Cardiovascular Risk Factors, Comorbidities, Medication Use and Procedural Variables on Remote Ischemic Conditioning Efficacy in Patients with ST-Segment Elevation Myocardial Infarction
- PMID: 31269650
- PMCID: PMC6650921
- DOI: 10.3390/ijms20133246
Influence of Cardiovascular Risk Factors, Comorbidities, Medication Use and Procedural Variables on Remote Ischemic Conditioning Efficacy in Patients with ST-Segment Elevation Myocardial Infarction
Abstract
Remote ischemic conditioning (RIC) confers cardioprotection in patients with ST-segment elevation myocardial infarction (STEMI). Despite intense research, the translation of RIC into clinical practice remains a challenge. This may, at least partly, be due to confounding factors that may modify the efficacy of RIC. The present review focuses on cardiovascular risk factors, comorbidities, medication use and procedural variables which may modify the efficacy of RIC in patients with STEMI. Findings of such efficacy modifiers are based on subgroup and post-hoc analyses and thus hold risk of type I and II errors. Although findings from studies evaluating influencing factors are often ambiguous, some but not all studies suggest that smoking, non-statin use, infarct location, area-at-risk of infarction, pre-procedural Thrombolysis in Myocardial Infarction (TIMI) flow, ischemia duration and coronary collateral blood flow to the infarct-related artery may influence on the cardioprotective efficacy of RIC. Results from the on-going CONDI2/ERIC-PPCI trial will determine any clinical implications of RIC in the treatment of patients with STEMI and predefined subgroup analyses will give further insight into influencing factors on the efficacy of RIC.
Keywords: ST-segment elevation myocardial infarction; acute myocardial infarction; ischemic preconditioning; post-infarction heart failure; remote ischemic conditioning.
Conflict of interest statement
M.R.S. is shareholder in CellAegisTM. K.P. and M.V.H. have no conflict of interest.
References
-
- Kristensen S.D., Laut K.G., Fajadet J., Kaifoszova Z., Kala P., Di Mario C., Wijns W., Clemmensen P., Agladze V., Antoniades L., et al. Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: Current status in 37 ESC countries. Eur. Heart J. 2014;35:1957–1970. doi: 10.1093/eurheartj/eht529. - DOI - PubMed
-
- Pedersen F., Butrymovich V., Kelbaek H., Wachtell K., Helqvist S., Kastrup J., Holmvang L., Clemmensen P., Engstrom T., Grande P., et al. Short- and long-term cause of death in patients treated with primary PCI for STEMI. J. Am. Coll. Cardiol. 2014;64:2101–2108. doi: 10.1016/j.jacc.2014.08.037. - DOI - PubMed
-
- Schmidt M., Jacobsen J.B., Lash T.L., Botker H.E., Sorensen H.T. 25 year trends in first time hospitalisation for acute myocardial infarction, subsequent short and long term mortality, and the prognostic impact of sex and comorbidity: A Danish nationwide cohort study. BMJ. 2012;344:e356. doi: 10.1136/bmj.e356. - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
